Javna agencija Republike Slovenije
za zdravila in medicinske pripomočke
Agency for Medicinal Products
and Medical Devices
of the Republic of Slovenia

Ptujska ulica 21
SI – 1000 Ljubljana
t + 386 (0)8 2000 500
f + 386 (0)8 2000 510
www.jazmp.si

Številka: 1382-4/2011
Datum : 10.2.2011

VSEM IMETNIKOM DOVOLJENJ ZA PROMET Z ZDRAVILI, KI VSEBUJEJO KORTIKOSTEROIDE ZA INHALIRANJE IN ZA INTRANAZALNO UPORABO

Zahteva za predložitev spremembe tipa IB – dopolnitev povzetka glavnih značilnosti zdravila in navodila za uporabo za zdravila, ki vsebujejo kortikosteroide za inhaliranje in za intranazalno uporabo

Spoštovani,

V novembru 2010 je delovna skupina za farmakovigilanco (PhVWP) pregledala in ocenila podatke o tveganju za psihiatrične neželene učinke pri uporabi kortikosteroidov za inhaliranje in pri intranazalni uporabi ter o tveganju za nepsihiatrične neželene učinke pri uporabi intranazalnih kortikosteroidov. Na osnovi ocene podatkov je zaključila, da je treba informacije v povzetku glavnih značilnosti zdravila in v navodilih za uporabo zadevnih zdravil ustrezno dopolniti.

Imetnike dovoljenj za promet z zadevnimi zdravili, ki še niso predložili vloge za spremembo prosimo, da Javni agenciji RS za zdravila in medicinske pripomočke v skladu s Pravilnikom o dovoljenju za promet z zdravilom za uporabo v humani medicini (Uradni list RS, št. 109/2010) in obvestilom JAZMP glede nove Uredbe Komisije (ES) št.1234/2008 z dne 24.11.2008 o pregledu sprememb pogojev dovoljenj za promet z zdravili za uporabo v humani medicini in zdravili za uporabo v veterinarski medicini predložijo spremembo tipa IB najkasneje v 60 dneh od objave obvestila. Dodatne informacije in podporna dokumentacija v vlogi niso potrebne.
Rok za implementacijo spremembe je 15. oktober 2011. Zdravila, izdelana po 15. januarju 2012, morajo biti opremljena z novim navodilom za uporabo.

V nadaljevanju vam podajamo odobreno originalno besedilo spremembe, objavljeno je tudi na spletni strani Vodij agencij za zdravila http://www.hma.eu/222.html.

S spoštovanjem,

JAVNA AGENCIJA REPUBLIKE SLOVENIJE ZA ZDRAVILA IN MEDICINSKE PRIPOMOČKE REPUBLIKA SLOVENIJA

dr. Martina Cvelbar, mag. farm., spec.
direktorica

Pripravila:
Katja Mohorčič, dipl.inž.lab.biomed.

Inhaled Corticosteroids

SUMMARY OF PRODUCT CHARACTERISTICS

- **Section 4.4**

It is proposed that a short statement should be included in section 4.4 of the SmPC for all inhaled steroids to alert prescribers to the potential for psychological and behavioural effects (alongside any warnings on systemic side-effects)

Proposed additional wording: (**bold and underlined** below)

Section 4.4 (Special warnings and precautions for use)

Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract, glaucoma, **and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children)**. *It is important therefore that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control of asthma is maintained.*

- **Section 4.8**

For section 4.8 of the SmPC, it is proposed that psychological and behavioural side-effects should be included for all inhaled steroids amongst other listed ADRs, as follows.

Section 4.8 (undesirable effects)		
System Organ Class	Adverse Event	Frequency
Psychiatric Disorders	**Psychomotor hyperactivity, sleep disorders, anxiety, depression, aggression, behavioural changes (predominantly in children)**	unknown*

**unless the MAH can designate a suitable frequency category according to the Guideline on Summary Of Product Characteristics*

PATIENT INFORMATION LEAFLET

The warnings on psychological and behavioural adverse reactions in the SmPC should be reflected in the Patient Information Leaflet using suitable lay terms and with information on the rarity of these reactions, if available.
It is also proposed that a general reminder to patients not to exceed the prescribed dose should be included in the leaflet, if not already included.

***Note**: wording for the PIL varies widely amongst products and the wording suggested below is largely based on patient-friendly wording taken from PILs which have undergone successful user-testing.*

Section 3
If you use more [product] than you should:
It is important that you take your dose as stated on the pharmacist's label or as advised by your doctor. You should not increase or decrease your dose without seeking medical advice.

Section 4
Frequency not known, but may also occur:
• Sleeping problems, depression or feeling worried, restless, nervous, over-excited or irritable. These effects are more likely to occur in children

Intranasal corticosteroids

SUMMARY OF PRODUCT CHARACTERISTICS

- **Section 4.4**

Section 4.4 of the UK SmPC for intranasal products already includes a statement on the risk of systemic side-effects, without specific examples of systemic ADRs. It is proposed to include examples of systemic ADRs to nasal steroids (including psychiatric effects) as a class effect in section 4.4, using wording which makes it clear these are less likely to occur with intranasal than oral steroids.

Section 4.4 (Special warnings and precautions for use)

Systemic effects of nasal corticosteroids may occur, particularly at high doses prescribed for prolonged periods. **These effects are much less likely to occur than with oral corticosteroids and may vary in individual patients and between different corticosteroid preparations. Potential systemic effects may include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children).**

PATIENT INFORMATION LEAFLET

The general warnings on systemic side-effects in section 4.8 of the SmPC should be reflected in the Patient Information Leaflet using suitable lay terms and with information on the rarity of these reactions. Since specific examples of effects which may occur are described in section 4.4 of the SmPC only, and are not proposed for inclusion in section 4.8, specific examples should not be included in section 4 of the Patient Information Leaflet as side-effects.

It is also proposed that a general reminder to patients not to exceed the prescribed dose should be included in the leaflet, if not already included.

***Note**: wording for the PIL varies widely amongst products and the wording suggested below is largely based on patient-friendly wording taken from PILs which have undergone successful user-testing.*

Section 3

If you use more [product] than you should:

It is important that you take your dose as stated on the pharmacist's label or as advised by your doctor. You should use only as much as your doctor recommends; using more or less may make your symptoms worse.